Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5 Head & Neck 2 Dermatologic 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 Classical hematology 1 CNS 1

Conditions

Cholangiocarcinoma 1

Interventions

Fluorouracil 286 Oxaliplatin 274 Gemcitabine 222 Capecitabine 221 Leucovorin 219 Bevacizumab 200 Irinotecan 170 pembrolizumab 141 Cisplatin 132 Cetuximab 111 Radiotherapy 109 Sorafenib 75 Nivolumab 75 130-nm albumin-bound paclitaxel 64 Paclitaxel 63 Albumin-Bound Paclitaxel 63 Docetaxel 61 Erlotinib Hydrochloride 57 Panitumumab 56 Radiosurgery 47 Folfox protocol 46 regorafenib 45 Sunitinib 40 Radiation 39 Magnetic Resonance Spectroscopy 38 durvalumab 33 Surgical Procedures, Operative 33 Ramucirumab 33 Trastuzumab 32 Cyclophosphamide 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Immunotherapy × Gastrointestinal × Clear all

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡